Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Troglitazone improves cardiac function in patients with congestive heart failure.

Kazuhide Ogino1, Yoshiyuki Furuse, Kazuhiko Uchida

  • 1Division of Cardiology, Department of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishimachi, Yonago 683-8504, Japan. k-ogino@umin.ac.jp

Cardiovascular Drugs and Therapy
|October 11, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Redefining Uric Acid and Cardiovascular Risk: Vascular Gout and Crystal-Driven Vascular Inflammation in Asymptomatic Hyperuricemia.

JACC. Asia·2026
Same author

Echocardiography Finds an Unusual Cause of Atrial Fibrillation.

CASE (Philadelphia, Pa.)·2026
Same author

First Japanese Case of Hereditary Transthyretin Amyloid Cardiomyopathy with an Ile68Leu Variant: A Case Report.

Internal medicine (Tokyo, Japan)·2026
Same author

Supra-skirtal leakage following subacute valve migration after TAVI.

Cardiovascular intervention and therapeutics·2026
Same author

Soluble uric acid enhances gouty inflammation via activating gene expression related to innate immune responses, M1 macrophage polarization and urate crystal phagocytosis in mouse macrophage-like cells: novel insights into its mechanisms from RNA sequencing.

Hypertension research : official journal of the Japanese Society of Hypertension·2026
Same author

Differential associations of transient hyperuricemia and transient hypouricemia with annual changes in estimated glomerular filtration rate in healthy participants: an observational study.

BMC nephrology·2026

Troglitazone improved heart function in diabetic patients with heart failure by increasing stroke volume and ejection fraction. This cardiac improvement occurred without altering blood pressure or activating the sympathetic nervous system.

Area of Science:

  • Cardiology
  • Pharmacology
  • Endocrinology

Background:

  • Troglitazone is known to improve cardiac output in diabetic patients with normal cardiac function.
  • The cardiovascular effects of troglitazone in patients with heart failure (HF) remain largely unknown.
  • Understanding these effects is crucial for managing diabetic patients with co-existing heart conditions.

Purpose of the Study:

  • To evaluate the acute cardiovascular effects of a single oral dose of troglitazone in type II diabetic patients with congestive heart failure.
  • To assess changes in hemodynamic parameters, cardiac function, and neurohormonal activity.
  • To determine if troglitazone induces positive inotropy in this patient population.

Main Methods:

  • A randomized, placebo-controlled study involving eight type II diabetic patients with congestive heart failure.

Related Experiment Videos

  • Administration of a single 400 mg dose of troglitazone or placebo.
  • Evaluation of blood pressure, echocardiographic findings, plasma catecholamines, and coefficient of variance of RR intervals (CVRR) at baseline and at 1, 2, 3, and 4 hours post-administration.

    • Main Results:

    • Troglitazone significantly increased left ventricular (LV) end-systolic dimension, % fractional shortening, E/A ratio, stroke volume, and LV ejection fraction compared to placebo.
    • No significant changes were observed in heart rate, blood pressure, or LV end-diastolic dimension.
    • Plasma catecholamines significantly decreased, while CVRR remained unchanged, indicating no sympathetic nervous system activation.

    Conclusions:

    • A single oral dose of troglitazone induces positive inotropic effects in diabetic patients with congestive heart failure.
    • These beneficial hemodynamic changes occur without sympathetic nervous system activation.
    • Troglitazone may represent a potential therapeutic option for improving cardiac function in diabetic patients with heart failure.